Skip to content
value.today

Hologic, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, -5.5% a year (statements).

%

US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt less cash at the end of FY2025 (statements); negative means more cash than debt.

What today's price assumes

The price's implied growth cannot be worked out with these figures (it needs a positive cash flow, a market value and a discount rate above long-run growth).

Cash-flow value of the shares
$7.5 B
Value of the whole business
$8.0 B
before net debt
Value from after year 10
38%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →-10.53%-8.03%-5.53%-3.03%-0.53%
8.15%—————
9.15%—————
10.15%—————
11.15%—————
12.15%—————

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Medical Instruments: $13.9 B to $34.7 B, median $24.0 BPrice to salesPrice to sales of Medical Instruments: $8.0 B to $27.2 B, median $14.2 BPrice to bookPrice to book of Medical Instruments: $10.0 B to $33.4 B, median $22.4 BCash-flow value$0 M$9.4 B$18.7 B$28.1 B$37.4 B

Your own DCF model

A full discounted-cash-flow model of Hologic, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Medical Instruments

Multiples of its companies with a market value at most 60 days old, times Hologic, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Hologic, Inc.Applied toValue (25th to 75th)Companies
P/E24.5× / 42.4× / 61.3×—net income $566 M$13.9 B to $34.7 B15
Price to sales2.0× / 3.5× / 6.6×—revenue $4.1 B$8.0 B to $27.2 B23
Price to book2.0× / 4.4× / 6.6×—book equity $5.0 B$10.0 B to $33.4 B23

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Hologic, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Mar 2026, each against its own median.

P/E

31.1×

Now above its median of 16.0×, in the top quarter of its range; range 9.4× to 38.4× over 6 months.

0×10×19×29×38×202120222023202420252026P/E 31×Median 16×

Price to sales

4.3×

Now above its median of 4.1×, in the top quarter of its range; range 3.1× to 5.0× over 6 months.

0×1×2×4×5×20202021202220232024Price to sales 4×Median 4×

Price to book

3.4×

Now below its median of 4.1×, in the bottom quarter of its range; range 3.4× to 6.9× over 7 months.

0×2×3×5×7×2020202120222023202420252026Price to book 3×Median 4×

as of Mar 8, 2026. Market caps: the dated values on file since 2020. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Mar 8, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Sep 27, 2025$4.1 B$566 M$1.1 B$59 M$998 M$548 MSEC annual report (10-K, 20-F)
FY2024to Sep 28, 2024$4.0 B$790 M$1.3 B$72 M$1.2 B$374 MSEC annual report (10-K, 20-F)
FY2023to Sep 30, 2023$4.0 B$456 M$1.1 B$92 M$959 M$96 MSEC annual report (10-K, 20-F)
FY2022to Sep 24, 2022$4.9 B$1.3 B$2.1 B$71 M$2.1 B$484 MSEC annual report (10-K, 20-F)
FY2021to Sep 25, 2021$5.6 B$1.9 B$2.3 B$118 M$2.2 B$1.9 BSEC annual report (10-K, 20-F)
FY2020to Sep 26, 2020$3.8 B$1.1 B$897 M$98 M$798 M$2.3 BSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value not on file.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.